HBP — Helix Biopharma Share News
0.000.00%
Last trade - 00:00- CA$75.61m
- CA$73.13m
Brief: Helix Biopharma successfully out-licenses late stage Biphasix technology
Brief: Helix Biopharma Corp signs non-binding letter of intent with Promab Biotechnologies to develop cell based therapies
Brief: Helix Biopharma Q1 loss per share C$0.04
Brief: Helix Biopharma presents topline L-DOS47 results
Brief: Helix Biopharma presents topline l-dos47 results
Brief: Helix Biopharma Corp accelerates escalation of l-dos47 dosing in the U.S. early-stage study
Brief: Helix Biopharma accelerates escalation of L-DOS47 dosing in the U.S. Phase I study
Brief: Helix BioPharma Corp announces fiscal 2016 results
Brief: Helix Biopharma announces deal with National Research Council of Canada
Brief: Helix Biopharma posts Q3 loss per share c$0.02
Brief: Helix Biopharm says trial steering committee made recommendation to initiate phase II component of LDOS002 study
Brief: Helix Biopharma says Patrick Frankham appointed COO
Brief: Helix Biopharma receives agreements totalling CAD4.7 mln for private placement financing
Brief: Helix Biopharma Sven Rohmann to step into CEO role, effective immediately
Brief: Helix Biopharma Q2 loss per share C$0.03
Brief: Helix Biopharma Q2 loss per share C$0.03
Brief: Helix Biopharma reports on advancement of its L-DOS47 phase I/II study in Poland
Brief: Helix Biopharma says till date L-DOS47 continues to be well tolerated by patients
Brief: Helix Biopharma announces appointment of new directors to the board of directors